Trump says ‘I am very proud of’ the COVID-19 vaccine
[brid autoplay=”true” video=”698512″ player=”23886″ title=”moderna%20looking%20good%206%20million%20doses” duration=”24″ description=”undefined” uploaddate=”2021-01-04″ thumbnailurl=”//cdn.brid.tv/live/partners/18168/thumb/698512_t_1609803251.png” contentUrl=”//cdn.brid.tv/live/partners/18168/sd/698512.mp4″]
By Jenny Goldsberry
Former President Trump blasted the Food and Drug Administration, claiming he had to “push” them during his term. Trump appeared on Hannity Tuesday to talk about, as he put it, his “great achievement” that was the COVID-19 vaccine.
“As far as a vaccine, I am very proud of it,” Trump said. “I pushed the FDA like they have never been pushed.” First, Dr. Anthony Fauci told Trump it would initially take three to five years to release a vaccine. Instead, it took nine months. Now, over 70% of Americans have received at lease one shot.
“I consider it a great achievement,” Trump said. “I would love people to take the vaccine. In the meantime, wear your mask if you want.” Meanwhile, the FDA also continues to encourage Americans to get the vaccine.
Trump himself got the vaccine during his term as president. At the time, the White House didn’t announce which vaccine he had. He, along with then First Lady Melania received their shots after contracting the virus.
You can follow Jenny Goldsberry on Twitter @jennyjournalism.
You may like
FDA will work with China to import cancer drugs due to U.S. shortages
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
You may like
Economy4 days ago
New York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
Economy4 days ago
Texas Gov Abbott aims to eliminate property taxes: ‘we must dream big’
Immigration3 days ago
Biden Administration to allow 40,000 asylum-seekers per month into US with mobile app
International3 days ago
Saudi Arabia-Israel Deal Remains Biden’s Win to Lose